Thilanga N. Pahattuge

Thilanga N. Pahattuge

Auto-generated profile, based on publicly available information

Thilanga N. Pahattuge

Department of Chemistry, The University of Kansas, Lawrence, KS 66045, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2022 in Science Advances
Verified
Journal Article
Open access
SGSachindra S. T. Gamage
Sachindra S. T. Gamage
TPThilanga N. Pahattuge
Thilanga N. Pahattuge
HWHarshani Wijerathne
Harshani Wijerathne
KCKatie Childers
Katie Childers
SVSwarnagowri Vaidyanathan
Swarnagowri Vaidyanathan
SSSteven Soper
Steven Soper
We report a microfluidic assay to select active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral particles (VPs), which were defined as intact particles with an accessible angiotensin-converting enzyme 2 receptor binding domain (RBD) on the spike (S) protein, from clinical samples. Affinity selection of SARS-CoV-2 particles was carried out using injection molded microfluidic chips, which allow for high-scale production to accommodate large-scale screening. The microfluidic contained a surface-bound aptamer directed against the virus’s S protein RBD to affinity select SARS-CoV-2 VPs. Following selection (~94% recovery), the VPs were released from the chip’s surface using a blue light light-emitting diode (89% efficiency). Selected SARS-CoV-2 VP enumeration was carried out using reverse transcription quantitative polymerase chain reaction. The VP selection assay successfully identified healthy donors (clinical specificity = 100%) and 19 of 20 patients with coronavirus disease 2019 (COVID-19) (95% sensitivity). In 15 patients with COVID-19, the presence of active SARS-CoV-2 VPs was found. The chip can be reprogrammed for any VP or exosomes by simply changing the affinity agent.